Research Article
Spleen Stiffness Predicts Survival after Transjugular Intrahepatic Portosystemic Shunt in Cirrhotic Patients
Table 1
Patient demographics, liver disease characteristics, and clinical presentation (median and ranges).
| | Variables | Overall population () | Death () | Survival () | value |
| | Age (yr) | 59 (30-80) | 59 (40-80) | 58 (30-78) | 0.045 | | Sex (male/female) | 54/35 | 16/8 | 38/27 | 0.626 | | Etiology of liver cirrhosis (viral/others) | 50/39 | 15/9 | 35/30 | 0.631 | | Indication for TIPS1 (bleeding/ascites/both) | 73/4/12 | 17/2/5 | 56/2/7 | 0.764 | | CTP2 score | 7 (5-10) | 8 (6-10) | 7 (5-10) | 0.019 | | CTP classification (A/B/C) | 24/62/3 | 4/18/2 | 20/44/1 | 0.147 | | MELD3 score | 10 (6-21) | 10.5 (7-21) | 10 (6-16) | 0.048 | | SB4 (μmol/L) | 16.4 (6.3-78.6) | 21.6 (6.8-78.6) | 16.1 (6.3-51.3) | 0.010 | | PLT5 (×1012/L) | 55 (16-207) | 46.5 (16-116) | 55 (22-207) | 0.348 | | PT6 (s) | 15.0 (11.5-20.1) | 15.7 (12.5-20.1) | 15.0 (11.5-19.4) | 0.114 | | ALT7 (IU/L) | 21.0 (5.2-136.7) | 22.5 (5.2-136.7) | 20.3 (6.0-66.2) | 0.857 | | AST8 (IU/L) | 26.6 (14.0-159.3) | 26.3 (18.8-159.3) | 26.7 (14-80.1) | 0.524 | | ALB9 (g/L) | 33.1 (19.8-40.0) | 32.2 (23.6-38.9) | 33.5 (19.8-40.0) | 0.482 | | Cr10 (μmol/L) | 64 (37-269) | 70 (47-269) | 62 (37-144) | 0.157 | | Mild PVT11 (yes/no) | 13/76 | 3/21 | 10/55 | 1.000 | | Ascites (no/mild/moderate/large) | 17/36/20/16 | 2/8/7/7 | 15/28/13/9 | 0.148 | | Liver stiffness (m/s) | 1.96 (1.46-3.39) | 2.08 (1.65-3.39) | 1.92 (1.46-2.99) | 0.025 | | Spleen stiffness (m/s) | 3.43 (2.82-4.04) | 3.60 (3.20-4.04) | 3.31 (2.82-3.74) | <0.001 |
|
|
Data are medians (ranges). 1TIPS: transjugular intrahepatic portosystemic shunt; 2CTP: Child-Turcotte-Pugh; 3MELD: model for end-stage liver disease; 4SB: serum bilirubin; 5PLT: platelet; 6PT: prothrombin time; 7ALT: alanine aminotransferase; 8AST: aspartate aminotransferase; 9ALB: albumin; 10Cr: creatinine; 11PVT: portal vein thrombosis.
|
